US equities |
MU $1,080.87 ▲+1.48% NVDA $231.20 ▲+1.23% SNDK $1,792.45 ▲+3.02% GOOGL $339.09 ▼-1.45% INTC $121.25 ▲+0.85% TSLA $356.73 ▲+0.54% SPCX $150.66 ▼-0.13% AMD $616.36 ▲+0.75%
FinancialContent Watchlist

Regeneron Pharmaceuticals (NQ:REGN)

740.75 -17.52 (-2.31%)
Delayed Quote Updated: 1:41 PM EDT, Oct 1, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 533,025
Open 766.53
Bid (Size) 740.41 (80)
Ask (Size) 741.63 (40)
Prev. Close 758.27
Today's Range 726.02 - 777.43
52wk Range 541.00 - 859.34
Shares Outstanding 91,779,465
Dividend Yield 0.51%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Why Regeneron (REGN) Stock Is Trading Lower Today
What Happened? Shares of biotech company Regeneron (NASDAQ:REGN) fell 4% in the afternoon session after the biotechnology company expanded its immunology all... 
Via StockStory
Which S&P500 stocks are moving on Thursday? ↗
Via Chartmill

Performance

YTD
-4.6%
-4.6%
1 Month
-7.3%
-7.3%
3 Month
+18.6%
+18.6%
6 Month
-4.7%
-4.7%
1 Year
+31.7%
+31.7%

More News

Read More
News headline image
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Phase 2 COURAGE Trial Confirms Trevogrumab Prevents Lean Mass and Muscle Loss During GLP-1 Receptor Agonist-induced Weight Loss
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron, Sanofi Expand Alliance in Deal Worth Up to $8 Billion ↗
Via MarketBeat
Topics ETFs
Regeneron Pharmaceuticals (NASDAQ:REGN): A Credible Value Stock With a Meaningful Discount ↗
Via Chartmill
News headline image
Regeneron and Sanofi Expand Global Alliance with Multiple Next-Generation, Long-Acting Immunology Antibodies
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Q2 Earnings Roundup: Incyte (NASDAQ:INCY) And The Rest Of The Biotechnology Segment
Via StockStory
Topics Artificial Intelligence
News headline image
Should You Buy Regeneron Pharmaceuticals Stock Before Oct. 30? ↗
Via The Motley Fool
News headline image
1 Profitable Stock with Impressive Fundamentals and 2 That Underwhelm
Via StockStory
News headline image
Regeneron to Report Third Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on October 30, 2026
From Regeneron Pharmaceuticals, Inc.
Via GlobeNewswire
News headline image
Regeneron Highlights EYLEA HD Momentum, Dupixent Growth and Pipeline Catalysts ↗
Via MarketBeat
Topics ETFs
News headline image
Is Regeneron Stock a Bargain Below $800? ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
1 S&P 500 Stock Worth Your Attention and 2 We Ignore
Via StockStory
Topics Stocks
News headline image
Novo Nordisk vs. Regeneron Pharmaceuticals: Which Healthcare Stock Is a Better Buy in 2026? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Regeneron Highlights Dupixent Growth, Cemdisiran Catalysts and EYLEA HD Momentum ↗
Via MarketBeat
Topics Intellectual Property
News headline image
CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Regeneron (REGN) Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
From Faruqi & Faruqi, LLP
Via Business Wire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via Business Wire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
Regeneron Eyes 2026 Catalysts as EYLEA HD and DUPIXENT Drive Growth ↗
Via MarketBeat
Topics ETFs
News headline image
REGN SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Regeneron Investors of Securities Class Action Lawsuit Deadline on September 14, 2026
From Faruqi & Faruqi LLP
Via GlobeNewswire
News headline image
MONDAY REGN INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces
From Robbins Geller Rudman & Dowd LLP
Via Business Wire
News headline image
REGENERNON PHARMACEUTICALS, INC. INVESTORS WITH LOSSES HAVE UNTIL SEPTEMBER 14, 2026 TO JOIN SECURITIES CLASS ACTION – Bernstein Liebhard LLP Announces Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
News headline image
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
From Schall, Brown & Schwartz LLP
Via GlobeNewswire
News headline image
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Regeneron Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines – REGN
From Pomerantz LLP
Via GlobeNewswire

Frequently Asked Questions

Is Regeneron Pharmaceuticals publicly traded?
Yes, Regeneron Pharmaceuticals is publicly traded.
What exchange does Regeneron Pharmaceuticals trade on?
Regeneron Pharmaceuticals trades on the Nasdaq Stock Market
What is the ticker symbol for Regeneron Pharmaceuticals?
The ticker symbol for Regeneron Pharmaceuticals is REGN on the Nasdaq Stock Market
What is the current price of Regeneron Pharmaceuticals?
The current price of Regeneron Pharmaceuticals is 740.75
When was Regeneron Pharmaceuticals last traded?
The last trade of Regeneron Pharmaceuticals was at 10/01/26 01:41 PM ET
What is the market capitalization of Regeneron Pharmaceuticals?
The market capitalization of Regeneron Pharmaceuticals is 67.99B
How many shares of Regeneron Pharmaceuticals are outstanding?
Regeneron Pharmaceuticals has 68B shares outstanding.